Summit Therapeutics (SMMT) Interest Expenses (2017 - 2024)

Summit Therapeutics (SMMT) has 10 years of Interest Expenses data on file, last reported at $71000.0 in Q2 2026.

• Quarterly Interest Expenses changed N/A year-over-year to $71000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $71000.0 (changed N/A YoY) and the FY2025 annual result came in at $3.7 million, down 99.78% from the prior year.
• Interest Expenses climbed to $71000.0 in Q2 2026, from $4000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $8.3 million in Q1 2023 to a low of $4000.0 in Q1 2026.
• A 5-year average of $2.6 million and a median of $2.9 million in 2023 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses surged 2703.7% — and 2025, when it tumbled 98.94%.
• Tracing SMMT's Interest Expenses over 5 years: stood at $2.9 million in 2022, then declined by 0.24% to $2.9 million in 2023, then surged by 152.16% to $7.3 million in 2024, then slumped by 99.55% to $33000.0 in 2025, then jumped by 115.15% to $71000.0 in 2026.
• The last three Interest Expenses figures came in at $71000.0 (Q2 2026), $4000.0 (Q1 2026), and $33000.0 (Q1 2025), per Business Quant data.